Health · Healthcare & Policy · 2 hrs ago
Rome’s Regina Elena cancer institute joins early-trial network
Rome’s Regina Elena cancer institute has joined START, an international network focused on early-stage cancer trials.
The partnership brings together START’s trial experience and the clinical and research expertise of Rome’s IFO hospitals.
It aims to widen access to experimental treatments for eligible patients in Rome, the Lazio region and across Italy.
Early-stage trials test new cancer treatments at an early point in their development.
The network has more than 45 lead investigators across 17 sites in the United States and Europe.
Italy records about 390,000 new cancer diagnoses each year, while clinical trial activity relative to its population is lower than in several other large European countries.
The partnership is intended to bring more patients into clinical research and strengthen links between treatment and innovation.
Rome’s Regina Elena cancer institute has joined the Start network for early-phase cancer clinical trials.
The partnership aims to expand eligible patients’ access to experimental cancer treatments through clinical studies.
The network has more than 45 principal investigators at 17 sites in the United States and Europe.
The collaboration brings Start’s early-trial experience together with the IFO institutes’ clinical and translational research expertise.
- Who
- The IFO institutes, including Rome’s Regina Elena National Cancer Institute, and the Start network.
- What
- The IFO institutes have joined Start’s network for early-phase cancer trials.
- When
- Not stated.
- Where
- Rome, Italy, as part of a network with sites in the United States and Europe.
- Why
- To expand eligible patients’ access to experimental cancer treatments and strengthen links between care and research.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Network
- More than 45 principal investigators
- Network sites
- 17 across the United States and Europe
- Partnership
- IFO institutes and Start
- Annual cancer diagnoses in Italy
- About 390,000
What people are saying
Italy has a significant impact from cancer diseases and world-class institutions, yet clinical trial activity relative to the population remains lower than in several other major European countries.
We see this partnership as an opportunity to bring more patients closer to early-phase clinical research, while also strengthening the integration of care and innovation.
New opportunities for collaboration and clinical research are opening up across a wide range of cancer conditions.